Efficacy and safety of roflumilast in the treatment of asthma

Eric D. Bateman, Jose Luis Izquierdo, Ulf Harnest, Peter Hofbauer, P. Magyar, Christine Wirlitsch, Stefan Leichtl, Dirk Bredenbröker

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Background: The central role of chronic inflammation of the airways in asthma pathogenesis is supported by the efficacy of corticosteroids in controlling clinical symptoms. However, the search continues for potentially safer anti-inflammatory alternatives. Roflumilast is an oral, once-daily phosphodiesterase type 4 inhibitor with anti-inflammatory activity in preclinical models of asthma and chronic obstructive pulmonary disease. Objective: To investigate the dose-ranging efficacy and safety of roflumilast in patients with mild-to-moderate asthma. Methods: Patients (N = 693) were randomized in a double-blind, parallel-group, phase 2/3 study. After a 1- to 3-week placebo run-in period, patients (mean forced expiratory volume in 1 second [FEV1], 73% of predicted) were randomized to receive 100, 250, or 500 μg of roflumilast once daily for 12 weeks. The primary end point was change from baseline in FEV1; secondary end points included change from baseline in morning and evening peak expiratory flow. Results: Roflumilast use significantly increased FEV1 (P <.001 vs baseline). Improvements from baseline in FEV, at the last visit were 260, 320, and 400 mL for the 100-, 250-, and 500-μg dose groups, respectively. Roflumilast, 500 μg, was superior to roflumilast, 100 μg, by 140 mL in improving FEV 1 (P = .002). There were also significant improvements from baseline in morning and evening peak expiratory flow in all the dose groups (P ≤ .006). Roflumilast was well tolerated at all doses tested. Most adverse events were mild to moderate in intensity and transient. Conclusion: These results support the emerging role of roflumilast, 500 μg/d, in the treatment of asthma.

Original languageEnglish
Pages (from-to)679-686
Number of pages8
JournalAnnals of Allergy, Asthma and Immunology
Volume96
Issue number5
Publication statusPublished - May 2006

Fingerprint

Asthma
Safety
Forced Expiratory Volume
Therapeutics
Anti-Inflammatory Agents
Phosphodiesterase 4 Inhibitors
Roflumilast
Chronic Obstructive Pulmonary Disease
Adrenal Cortex Hormones
Placebos
Inflammation

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Bateman, E. D., Izquierdo, J. L., Harnest, U., Hofbauer, P., Magyar, P., Wirlitsch, C., ... Bredenbröker, D. (2006). Efficacy and safety of roflumilast in the treatment of asthma. Annals of Allergy, Asthma and Immunology, 96(5), 679-686.

Efficacy and safety of roflumilast in the treatment of asthma. / Bateman, Eric D.; Izquierdo, Jose Luis; Harnest, Ulf; Hofbauer, Peter; Magyar, P.; Wirlitsch, Christine; Leichtl, Stefan; Bredenbröker, Dirk.

In: Annals of Allergy, Asthma and Immunology, Vol. 96, No. 5, 05.2006, p. 679-686.

Research output: Contribution to journalArticle

Bateman, ED, Izquierdo, JL, Harnest, U, Hofbauer, P, Magyar, P, Wirlitsch, C, Leichtl, S & Bredenbröker, D 2006, 'Efficacy and safety of roflumilast in the treatment of asthma', Annals of Allergy, Asthma and Immunology, vol. 96, no. 5, pp. 679-686.
Bateman ED, Izquierdo JL, Harnest U, Hofbauer P, Magyar P, Wirlitsch C et al. Efficacy and safety of roflumilast in the treatment of asthma. Annals of Allergy, Asthma and Immunology. 2006 May;96(5):679-686.
Bateman, Eric D. ; Izquierdo, Jose Luis ; Harnest, Ulf ; Hofbauer, Peter ; Magyar, P. ; Wirlitsch, Christine ; Leichtl, Stefan ; Bredenbröker, Dirk. / Efficacy and safety of roflumilast in the treatment of asthma. In: Annals of Allergy, Asthma and Immunology. 2006 ; Vol. 96, No. 5. pp. 679-686.
@article{3c4dfa9237f44072845dee4e2e904085,
title = "Efficacy and safety of roflumilast in the treatment of asthma",
abstract = "Background: The central role of chronic inflammation of the airways in asthma pathogenesis is supported by the efficacy of corticosteroids in controlling clinical symptoms. However, the search continues for potentially safer anti-inflammatory alternatives. Roflumilast is an oral, once-daily phosphodiesterase type 4 inhibitor with anti-inflammatory activity in preclinical models of asthma and chronic obstructive pulmonary disease. Objective: To investigate the dose-ranging efficacy and safety of roflumilast in patients with mild-to-moderate asthma. Methods: Patients (N = 693) were randomized in a double-blind, parallel-group, phase 2/3 study. After a 1- to 3-week placebo run-in period, patients (mean forced expiratory volume in 1 second [FEV1], 73{\%} of predicted) were randomized to receive 100, 250, or 500 μg of roflumilast once daily for 12 weeks. The primary end point was change from baseline in FEV1; secondary end points included change from baseline in morning and evening peak expiratory flow. Results: Roflumilast use significantly increased FEV1 (P <.001 vs baseline). Improvements from baseline in FEV, at the last visit were 260, 320, and 400 mL for the 100-, 250-, and 500-μg dose groups, respectively. Roflumilast, 500 μg, was superior to roflumilast, 100 μg, by 140 mL in improving FEV 1 (P = .002). There were also significant improvements from baseline in morning and evening peak expiratory flow in all the dose groups (P ≤ .006). Roflumilast was well tolerated at all doses tested. Most adverse events were mild to moderate in intensity and transient. Conclusion: These results support the emerging role of roflumilast, 500 μg/d, in the treatment of asthma.",
author = "Bateman, {Eric D.} and Izquierdo, {Jose Luis} and Ulf Harnest and Peter Hofbauer and P. Magyar and Christine Wirlitsch and Stefan Leichtl and Dirk Bredenbr{\"o}ker",
year = "2006",
month = "5",
language = "English",
volume = "96",
pages = "679--686",
journal = "Annals of Allergy, Asthma and Immunology",
issn = "1081-1206",
publisher = "American College of Allergy, Asthma and Immunology",
number = "5",

}

TY - JOUR

T1 - Efficacy and safety of roflumilast in the treatment of asthma

AU - Bateman, Eric D.

AU - Izquierdo, Jose Luis

AU - Harnest, Ulf

AU - Hofbauer, Peter

AU - Magyar, P.

AU - Wirlitsch, Christine

AU - Leichtl, Stefan

AU - Bredenbröker, Dirk

PY - 2006/5

Y1 - 2006/5

N2 - Background: The central role of chronic inflammation of the airways in asthma pathogenesis is supported by the efficacy of corticosteroids in controlling clinical symptoms. However, the search continues for potentially safer anti-inflammatory alternatives. Roflumilast is an oral, once-daily phosphodiesterase type 4 inhibitor with anti-inflammatory activity in preclinical models of asthma and chronic obstructive pulmonary disease. Objective: To investigate the dose-ranging efficacy and safety of roflumilast in patients with mild-to-moderate asthma. Methods: Patients (N = 693) were randomized in a double-blind, parallel-group, phase 2/3 study. After a 1- to 3-week placebo run-in period, patients (mean forced expiratory volume in 1 second [FEV1], 73% of predicted) were randomized to receive 100, 250, or 500 μg of roflumilast once daily for 12 weeks. The primary end point was change from baseline in FEV1; secondary end points included change from baseline in morning and evening peak expiratory flow. Results: Roflumilast use significantly increased FEV1 (P <.001 vs baseline). Improvements from baseline in FEV, at the last visit were 260, 320, and 400 mL for the 100-, 250-, and 500-μg dose groups, respectively. Roflumilast, 500 μg, was superior to roflumilast, 100 μg, by 140 mL in improving FEV 1 (P = .002). There were also significant improvements from baseline in morning and evening peak expiratory flow in all the dose groups (P ≤ .006). Roflumilast was well tolerated at all doses tested. Most adverse events were mild to moderate in intensity and transient. Conclusion: These results support the emerging role of roflumilast, 500 μg/d, in the treatment of asthma.

AB - Background: The central role of chronic inflammation of the airways in asthma pathogenesis is supported by the efficacy of corticosteroids in controlling clinical symptoms. However, the search continues for potentially safer anti-inflammatory alternatives. Roflumilast is an oral, once-daily phosphodiesterase type 4 inhibitor with anti-inflammatory activity in preclinical models of asthma and chronic obstructive pulmonary disease. Objective: To investigate the dose-ranging efficacy and safety of roflumilast in patients with mild-to-moderate asthma. Methods: Patients (N = 693) were randomized in a double-blind, parallel-group, phase 2/3 study. After a 1- to 3-week placebo run-in period, patients (mean forced expiratory volume in 1 second [FEV1], 73% of predicted) were randomized to receive 100, 250, or 500 μg of roflumilast once daily for 12 weeks. The primary end point was change from baseline in FEV1; secondary end points included change from baseline in morning and evening peak expiratory flow. Results: Roflumilast use significantly increased FEV1 (P <.001 vs baseline). Improvements from baseline in FEV, at the last visit were 260, 320, and 400 mL for the 100-, 250-, and 500-μg dose groups, respectively. Roflumilast, 500 μg, was superior to roflumilast, 100 μg, by 140 mL in improving FEV 1 (P = .002). There were also significant improvements from baseline in morning and evening peak expiratory flow in all the dose groups (P ≤ .006). Roflumilast was well tolerated at all doses tested. Most adverse events were mild to moderate in intensity and transient. Conclusion: These results support the emerging role of roflumilast, 500 μg/d, in the treatment of asthma.

UR - http://www.scopus.com/inward/record.url?scp=33646740035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646740035&partnerID=8YFLogxK

M3 - Article

C2 - 16729780

AN - SCOPUS:33646740035

VL - 96

SP - 679

EP - 686

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

SN - 1081-1206

IS - 5

ER -